Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2000 1
2001 5
2002 4
2003 5
2004 4
2006 4
2007 3
2008 3
2009 5
2010 6
2011 5
2012 10
2013 15
2014 5
2015 3
2016 8
2017 5
2018 9
2019 16
2020 11
2021 7
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20737201

120 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
Gärtner BC, Schäfer H, Marggraff K, Eisele G, Schäfer M, Dilloo D, Roemer K, Laws HJ, Sester M, Sester U, Einsele H, Mueller-Lantzsch N. Gärtner BC, et al. J Clin Microbiol. 2002 Feb;40(2):351-8. doi: 10.1128/JCM.40.2.351-358.2002. J Clin Microbiol. 2002. PMID: 11825941 Free PMC article.
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, Schumm M, Stevanovic S, Handgretinger R, Lang P, Feuchtinger T. Icheva V, et al. J Clin Oncol. 2013 Jan 1;31(1):39-48. doi: 10.1200/JCO.2011.39.8495. Epub 2012 Nov 19. J Clin Oncol. 2013. PMID: 23169501
Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ. Worth A, et al. Br J Haematol. 2011 Nov;155(3):377-85. doi: 10.1111/j.1365-2141.2011.08855.x. Epub 2011 Sep 13. Br J Haematol. 2011. PMID: 21910716 Free article.
Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV. Patel C, et al. Transplant Cell Ther. 2023 Feb;29(2):132.e1-132.e5. doi: 10.1016/j.jtct.2022.10.023. Epub 2022 Nov 9. Transplant Cell Ther. 2023. PMID: 36334653 Free article.
120 results